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Background: The prognosis for patients diagnosed with non small cell 
lung cancer is poor and research efforts are being directed towards the 
development of novel research models to predict patterns of failure or 
success in non surgically treated patients with NSCLC. 
Objective: 1. To determine if there is a difference in the proportions of 
histological cell types between LTS the patients who live greater than 
3 years without surgery when compared to the patient population in the 
Thoracic Data Base (TDB). 2. To determine if there is a meaningful dif-
ference in the proportions of “B” symptoms in the LTS group. 
Methods: In a retrospective analysis of MD Anderson Cancer Center 
(MDACC) tumor registry, we identiﬁed all pts diagnosed with non 
small cell lung cancer (NSCLC) from 1991-2001. Those with surgi-
cal resection were excluded. In addition, we prospectively identiﬁed a 
reference group of NSCLC patients through the MDACC Thoracic date 
base (TDB) treated in our department since 2002. Histologic cell types 
were grouped according to: Adenocarcinoma (A), Bronchioloalveolar 
(BAC) Squamous (S), NSCLC, Not Otherwise Speciﬁed (NSC/NOS) 
and Large Cell Neuroendocrine (L) and the two databases were com-
pared for differences. Clinical records of all patients in the LTS group 
were reviewed for weight loss, fever, and fatigue. 
Results: 14,764 patients were seen with a primary diagnosis of 
NSCLC. 5,114 received initial treatment at MDACC. 1,925 had 
surgery. LTS was achieved in 294 of 3,189 (9.2%) who were treated 
with radiation, chemotherapy or combined modality therapy. Median 
survival for LTS was 5.2 years. Histologic subtyping was available for 
in all 294 LTS pts and 2,034 TDB pts. Histology subtypes are shown in 
Table I below.
Histology
TDB  
(Total=
2034)
Number of 
Patients
Percent-
age
LTS  
(Total=
293)
Number  
of Pts
Percentage
Adeno  1020  50.1%  128 43.7%
Adeno/BAC  90 4.4%  11 3.8%
Squamous  384 18.9%  72 24.6%
NSC/NOS  492 24.2%  69 23.5%
Large cell  48 2.4%  13 4.4%
In the LTS arm the rates of “B” symptoms were: Fever, 15/294(5.1%), 
Fatigue, 23/294(7.8%), No symptoms 255/294 (86.7%), weight loss 
104/294(35.4%), no weight loss 191/294 (64.6%). 
Conclusions: Squamous subtype was over-represented in LTS pts 
compared to Adenocarcinoma. (chi-square test p=0.0274) There was 
no apparent excess in BAC as might have been expected. Although the 
numbers are small, Large Cell histology was also higher than expected. 
Discussion: Histologic subtypes of NSCLC have taken on increasing 
importance in the era of targeted therapy. Our analysis suggests that 
prognostic models should increasingly include histology and presence 
or absence of “B” symptoms.
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Introduction: Solitary brain metastases occur in about 50% of patients 
with brain metastases from non small cell lung cancer. The standard 
therapy is surgical resection or stereotactic radiosurgery plus whole 
brain radiotherapy. The optimal treatment for the primary site of newly 
diagnosed non small cell lung cancer with solitary brain metastases is 
not well deﬁned.
Purpose: to evaluate the outcome of treatment for patients with newly 
diagnosis advanced non small cell lung cancer with isolated single 
synchronous brain metastases. 
Material and Methods: A total of 22 patients with non small cell lung 
cancer and solitary brain metastases were included. All patients had 
extensive tumour non small cell lung cancer with involved mediasti-
nal lymph nodes. 4 patients received treatment of their primary lung 
cancer using radiotherapy, 6 patients treated with chemotherapy and 12 
patients treated with both chemotherapy and radiotherapy.
The treatment of brain metastases was as follows: 14 patients under-
went surgery resection and postoperative whole brain radiotherapy, 4 
had surgical resection alone and 4 treated with radiotherapy alone. Sur-
vival was measured from the date of the ﬁrst treatment for malignancy.
Results: Overall survival from time of lung cancer diagnoses were 1 
year survival rate 36, 3%, 2-year 9%. The better overall survival was 
achieved in patients treated with chemo and radiotherapy. A total of 6 
(27, 2%) patients had failure in brain, including 3 patients who receiv-
ing whole brain irradiation alone.
Conclusion: Aggressive therapy for both, primary site of non small cell 
lung cancer and the brain metastases may provide a survival advan-
tages. Better local control of single brain metastases was achieved with 
a combination of whole brain radiotherapy with surgical resection.
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Background: Long term survival (LTS) is the ultimate goal of success-
ful treatment in non small cell lung cancer (NSCLC). Unfortunately, 
surgery is not an option for most pts and LTS is less likely without 
surgery. Although performance status (PS), gender, and stage are estab-
lished key prognostic variables, more information is needed regarding 
other predictors of success or failure. 
Objective: We analyzed the impact of tumor location in pts with 
NSCLC who lived 3 years or longer without surgery.
Methods: Using the MDACC Thoracic Database (TDB), we reviewed 
records of all pts with NSCLC diagnosed from 1991-2001 excluding 
those having pneumonectomy, lobectomy, segmental, or wedge resec-
tion. We analyzed tumors according to upper, lower, middle, or central 
location and compared them to our ongoing prospective TDB. 
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Results: 14,764 pts were seen with a primary diagnosis of NSCLC. 
5,114 received initial treatment at MDACC. 1,925 had surgery alone or 
with a multidisciplinary approach. LTS was achieved in 294 of 3,189 
(9.2%) who had only radiation therapy, chemotherapy or some combi-
nation of both. Median survival for LTS was 5.2 years. Stages: IA=29 
(9.9%), IB=18 (6.1%), IIA=4 (1.4%), IIB=2 (0.7%), IIIA=56 (19.0%), 
IIIB=98 (33.3%), and STAGE IV=87 (29.6%).
# Pts
Upper 
Lobe
Lower 
Lobe
Middle/ 
Lingula
Central
Rad 
Only
Chemo 
Only
Chemo 
& Rad
IA 29 21 6  2 29   
IB 18 10 7  1 16 1 1
IIA 4 3 1   1  3
IIB 2 2    2   
IIIA 56 42 5 1 8 9 3 44
IIIB 98 63 9 4 22 19 9 70
IV 87 48 19 4 8 15 60 12
III & IV 
Only 241 153 33 9 38 XXXXX XXXXX XXXXX
All 
Patients 294 189 47 9 41 91 73 130
Upper lobe lesions made up 189/294 (64.3%) LTS cases versus 47 
lower lobe lesions (16.0%) with 9 middle lobe or lingula. The re-
mainder were central. The ratio of upper to lower lobe lesions was 4:1 
- dramatically different from the usual 2:1 ratio (p=0.0002). The ratio is 
even more pronounced taking Stages III & IV only. 
Conclusions: Upper lobe lesions - especially RUL - appear signiﬁ-
cantly more common than lower lobe lesions in LTS of NSCLC treated 
without surgery. 
Discussion: Prognostic models of NSCLC will be improved by includ-
ing location of the primary tumor. 
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Background: To investigate the role of WPC and concurrent TR as 
neoadjuvant therapy before S for the patients with pN2-stage IIIA 
NSCLC.
Methods: Patients with pN2 and operable stage IIIA NSCLC were 
eligible. Six weekly chemotherapies with paclitaxel (50mg/m2)/cispla-
tin (20mg/m2) were given with concurrent TR (1.8Gy/day x 5/week, 45 
Gy) during 5 weeks. Chest CT, FDG-PET scan were checked before 
and 3 weeks after chemoradiation. S was performed at least 4 weeks 
after concurrent chemoradiation. For the patients without clearing pN2 
nodes or with pT3 after S, boost radiation (20Gy) was given.
Results: From January 2002 to February 2006, 41 patients were 
enrolled. The median follow up time was 27.2 months: gender (male: 
female, 31: 10), age (median 56, 44-67 years old). Of them, 35 patients 
underwent S. Three patients showed brain metastasis during chemo-
radiation (but one patient underwent S after gamma knife surgery of 
single brain metastasis). Two patients refused S after chemoradiation. 
One patient showed severe radiation pneumonitis and was not ﬁt for S. 
One patient showed lung to lung metastases before S. Eighteen patients 
(43.9%) showed pN0-1, and 9 patients (22.0%) showed pathologic 
complete remission (CR). Four year progression free survival and 
overall survival were 44.0% (median 21.2 months) and 42.6% (median 
35.4 months). In univariate analysis clearing N2 node and pahologic 
CR after S were the facts that could predict long term survival. Grade 3 
or 4 toxicities during WPC included anemia (7.3%), neutropenia (6%), 
thrombocytopenia (2.4%), Hypersensitivity reaction (2.4%), radiation 
pneumonitis (12.2%), and radiation esophagitis (7.3%). There was no 
treatment-related death.
Conclusions: WPC with concurrent TR followed by S for pN2 stage 
IIIA NSCLC was feasible. Clearing N2 nodes or pathologic CR after S 
were the facts of long tern survival. 
P2-190 NSCLC: Combined Modality Therapy Posters, Tue, Sept 4 
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Background: The prognosis of patients with stage III non-small cell 
lung cancer (NSCLC) who achieved pathological complete response or 
downstaging following neoadjuvant chemotherapy is better than those 
with residual metastatic lymph node (LN). However, the prognostic 
signiﬁcance of the number of residual metastatic LNs remains unclear. 
Methods: From January 2001 to January 2006, 42 consecutive patients 
with stage IIIAN2 (22 patients) and IIIB without pleural effusion (20 
patients) were treated with neoadjuvant chemotherapy. Thirty four of 
42 patients were pathologically staged by mediastinoscopy. Neoadju-
vant chemotherapy consisted of 3 cycles of platinum based doublet (21 
patients with gemcitabine, 15 with paclitaxel, and 6 with docetaxel). 
Results: After neoadjuvant chemotherapy, pathological complete 
response and downstaging was achieved in one patient and 24 patients, 
respectively. No pathological LN metastasis was present in 9 patients 
(21.4%), and LN metastasis was present in 33 patients (78.6%). With a 
median follow up of 23 months, the 2-year disease free survival (DFS) 
rate of patients without residual LN metastasis was statistically better 
than that of patients with residual LN metastasis (46% and 18% in 
patients with residual LN, p=0.03). Among 33 patients with residual 
LN metastasis, age (p=0.01), pathological downstaging (p=0.09) and 
number of residual metastatic LNs (median 14 months in LN ≤4 vs 
median 5 months in LN ≥5; p=0.01) were signiﬁcant predictors of DFS 
in univariate analysis. In multivariate analysis, number of residual 
metastatic LNs was an independent predictor of DFS among patients 
with residual LN metastasis, irrespective of pathological downstaging.
Conclusion: The number of residual metastatic lymph nodes follow-
ing neoadjuvant chemotharpy is an independent predictor of DFS in 
patients with stage III NSCLC.
